Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Daily Online Adaptive Short-Course Radiation Therapy and Concurrent Chemotherapy for Muscle-Invasive Bladder Cancer: A Prospective Trial of an Individualized Approach for Reducing Bowel and Bladder Toxicity (ARTIA-Bladder)

NCT05700227 is registered in ClinicalTrials.gov with Varian, a Siemens Healthineers Company as lead sponsor.

NCT NCT05700227
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05700227 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Daily Online Adaptive Short-Course Radiation Therapy and Concurrent Chemotherapy for Muscle-Invasive Bladder Cancer: A Prospective Trial of an Individualized Approach for Reducing Bowel and Bladder Toxicity (ARTIA-Bladder)
Lead sponsor
Varian, a Siemens Healthineers Company
Phase
Not applicable
Overall status
Terminated
Start date
February 2, 2023
Completion date
May 9, 2024
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

muscle invasive bladder urothelial carcinoma